ArticleImmunotherapy2023
Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center.
Article in Immunotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Real world incidence, predictors and outcomes of endocrine immune-related adverse events following immune checkpoint inhibitors.Human vaccines & immunotherapeutics · 2026Article
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review.Frontiers in endocrinology · 2026Review
- Etiologies and Outcomes of Diabetic Ketoacidosis in Cancer Patients: A Retrospective Analysis.Cancers · 2025Article
- Risk Factors Associated with the Development of Immune-Checkpoint Inhibitor Diabetes Mellitus: An Integrative Review.Life (Basel, Switzerland) · 2025Review
- Immune checkpoint inhibitors: From friend to foe.Toxicology reports · 2025Article
- Review
- Immunotherapy in gestational trophoblastic neoplasia: advances and future directions.Frontiers in immunology · 2025Review
- Clinical characteristics and prognosis of pancreatitis associated with immune checkpoint inhibitors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy.Current oncology reports · 2024Review
- Toxicity in the era of immune checkpoint inhibitor therapy.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.